Walder Wyss: Nagi Bioscience raises CHF 12.4m

Walder Wyss has advised co-led investors Swisscanto and imec.xpand in connection with Nagi Bioscience’s Series A Financing round in the amount of CHF 12.4 million. The Swiss life sciences startup has secured an oversubscribed investment from top-tier venture capital firms across Europe with the aim to open new markets. Nagi is a life sciences company developing next-generation laboratory equipment to unlock the full potential of alternatives to animal testing.

The round was co-led by Swisscanto and imec.xpand, together with the participation of Excellis Holding and existing investors Verve Ventures and Zürcher Kantonalbank. Swisscanto is the asset management arm of the Zürcher Kantonalbank, one of Switzerland’s largest fund providers, developing high-quality investment and pension solutions for private investors, companies and institutions. imec.xpand is an early stage and growth venture capital fund with a game-changing approach to turn hardware driven nanotechnology innovation into successful global companies.

The team was led by partner Alexandre Both (corporate/M&A, pictured) and included associate Sébastien Aubert and senior associate Alexander Sorton (both corporate/M&A).